Cytogenetic Abnormalities in Patients with Acute Myelogenous Leukemia with Lymphoid Markers.
- Author:
Yoon Hwan CHANG
1
;
Dong Soon LEE
;
Sung Sup PARK
;
Ji Yeon KIM
;
Myoung Hee PARK
;
Byoung Kook KIM
;
Seonyang PARK
;
Hyo Seop AHN
;
Hee Young SHIN
;
Han Ik CHO
Author Information
1. Department of Clinical Pathology, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
AML;
Lymphoid markers;
Cytogenetic abnormalities
- MeSH:
Biomarkers;
Chromosome Aberrations*;
Cytogenetics*;
Diagnosis;
Diagnosis, Differential;
Humans;
Immunophenotyping;
Leukemia;
Leukemia, Myeloid, Acute*;
Prognosis
- From:Korean Journal of Clinical Pathology
1998;18(4):516-524
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Immunologic marker studies and cytogenetic studies as well as morphological studies are frequently performed for the differential diagnosis of acute leukemia. We investigated the relationship of between immunophenotyping and cytogenetic abnormalities in acute myelogenous leukemias (AMLs). METHODS: Total 153 cases of AMLs were included. Morphological, cytochemical, immunophenotypic, and cytogenetic studies were performed. We classified the AML cases according to immunophenotyping and investigated the association between cytogenetic results and immunophenotype. And we compared differences between the AML group with lymphoid markers and that without them. RESULTS: In 153 cases of AMLs, lymphoid markers (CD2, CD5, CD7, CD19, CD10) were coexpressed in 59 cases (38.6%). Cytogenetic abnormalities were in 106 cases (69.3%). No significant difference in cytogenetic abnormalities was observed between the group with lymphoid markers and without them (76.3% vs. 64.9%, P>0.05). t(8;21)(q22;22) was significantly more frequent in CD19+AMLs (78.3% vs. 7.7%, P<0.0001), compared to CD19-AMLs. In CD2+AMLs, t(15;17)(q24;q21) was significantly more frequent than in CD2-AMLs (81.8% vs. 8.5%, P<0.0001). CD7+AML cases showed fewer cytogenetic abnormalities than AML with other lymphoid markers and various chromosomal abnormalities. CONCLUSIONS: In AML, cytogenetic abnormalities were different in relation to aberrant lymphoid markers. CD19 vs. t(8;21) and CD2 vs. t(15;17) were closely associated with each other. It is thought that CD7+AML cases are heterogeneous group. We need the study for response to therapy and prognosis in AMLs with lymphoid markers so that the data of this study can be helpful for the diagnosis and treatment.
